Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors
Krishna Murthy P, Karthikeyan Sivashanmugam, Mahesh Kandasamy, S. Rajasekaran, Vilwanathan Ravikumar
Topics & Concepts
Pulmonary fibrosisMedicineFavipiravirDrug repositioningPandemicDiseaseHistone deacetylaseIntensive care medicineImmunologyFibrosisCoronavirus disease 2019 (COVID-19)DrugPharmacologyInternal medicineBiologyHistoneInfectious disease (medical specialty)BiochemistryGeneInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisCOVID-19 Clinical Research StudiesAutophagy in Disease and Therapy